Mariangela Pierantozzi

List of Publications by Citations

104 papers	3,537 citations	33 h-index	57 g-index
104 ext. papers	4,061 ext. citations	4 avg, IF	4.85 L-index

#	Paper	IF	Citations
104	Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease. *Brain*, **2007**, 130, 1596-607	11.2	641
103	Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. *Brain*, **2010**, 133, 3423-33	11.2	315
102	High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients. *Annals of Neurology*, **2005**, 57, 777-9	9.4	122
101	Subthalamic stimulation activates internal pallidus: evidence from cGMP microdialysis in PD patients. *Annals of Neurology*, **2005**, 57, 448-52	9.4	104
100	Biochemical and electrophysiological changes of substantia nigra pars reticulata driven by subthalamic stimulation in patients with Parkinson's disease. *European Journal of Neuroscience*, **2006**, 23, 2923-8	3.5	95
99	Subjective neurological symptoms frequently occur in patients with SARS-CoV2 infection. *Brain, Behavior, and Immunity*, **2020**, 88, 11-16	16.6	95
98	Non-motor functions in parkinsonian patients implanted in the pedunculopontine nucleus: focus on sleep and cognitive domains. *Journal of the Neurological Sciences*, **2010**, 289, 44-8	3.2	93
97	Increased blood-cerebrospinal fluid transfer of albumin in advanced Parkinson's disease. *Journal of Neuroinflammation*, **2012**, 9, 188	10.1	92
96	Dysbiosis of gut microbiota in a selected population of Parkinson's patients. *Parkinsonism and Related Disorders*, **2019**, 65, 124-130	3.6	86
95	Stimulation of the subthalamic nucleus compared with the globus pallidus internus in patients with Parkinson disease. *Journal of Neurosurgery*, **2004**, 101, 195-200	3.2	80
94	Multi-target strategy for Parkinsonian patients: the role of deep brain stimulation in the centromedian-parafascicularis complex. *Brain Research Bulletin*, **2009**, 78, 113-8	3.9	74
93	123I-FP-CIT semi-quantitative SPECT detects preclinical bilateral dopaminergic deficit in early Parkinson's disease with unilateral symptoms. *Nuclear Medicine Communications*, **2005**, 26, 421-6	1.6	67
92	CSF biomarkers, impairment of cerebral hemodynamics and degree of cognitive decline in Alzheimer's and mixed dementia. *Journal of the Neurological Sciences*, **2009**, 283, 109-15	3.2	62
91	Dietary Vitamin E as a Protective Factor for Parkinson's Disease: Clinical and Experimental Evidence. *Frontiers in Neurology*, **2019**, 10, 148	4.1	53
90	Effects of deep brain stimulation of the peduncolopontine area on working memory tasks in patients with Parkinson's disease. *Parkinsonism and Related Disorders*, **2010**, 16, 64-7	3.6	51
89	Pedunculopontine nucleus deep brain stimulation changes spinal cord excitability in Parkinson's disease patients. *Journal of Neural Transmission*, **2008**, 115, 731-5	4.3	51
88	Deep brain stimulation of pedunculopontine tegmental nucleus: role in sleep modulation in advanced Parkinson disease patients: one-year follow-up. *Sleep*, **2012**, 35, 1637-42	1.1	50

87	Cerebrospinal fluid lactate levels and brain [18F]FDG PET hypometabolism within the default mode network in Alzheimer's disease. *European Journal of Nuclear Medicine and Molecular Imaging*, **2016**, 43, 2040-9	8.8	50
86	The effect of levodopa therapy on dopamine transporter SPECT imaging with(123)I-FP-CIT in patients with Parkinson's disease. *European Journal of Nuclear Medicine and Molecular Imaging*, **2005**, 32, 1452-6	8.8	48
85	AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis. *Journal of the Neurological Sciences*, **2005**, 237, 83-8	3.2	46
84	Correlation between changes in CSF dopamine turnover and development of dyskinesia in Parkinson's disease. *Parkinsonism and Related Disorders*, **2009**, 15, 383-9	3.6	44
83	Effect of Vigabatrin on motor responses to transcranial magnetic stimulation: an effective tool to investigate in vivo GABAergic cortical inhibition in humans. *Brain Research*, **2004**, 1028, 1-8	3.7	43
82	Rotigotine may improve sleep architecture in Parkinson's disease: a double-blind, randomized, placebo-controlled polysomnographic study. *Sleep Medicine*, **2016**, 21, 140-4	4.6	42
81	CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment. *Journal of the Neurological Sciences*, **2006**, 251, 124-8	3.2	41
80	Self-reported needs of patients with Parkinson's disease during COVID-19 emergency in Italy. *Neurological Sciences*, **2020**, 41, 1373-1375	3.5	39
79	Intensity-dependent facial emotion recognition and cognitive functions in Parkinson's disease. *Journal of the International Neuropsychological Society*, **2010**, 16, 867-76	3.1	39
78	Grammar improvement following deep brain stimulation of the subthalamic and the pedunculopontine nuclei in advanced Parkinson's disease: a pilot study. *Parkinsonism and Related Disorders*, **2009**, 15, 606-9	3.6	39
77	Systemic activation of Nrf2 pathway in Parkinson's disease. *Movement Disorders*, **2020**, 35, 180-184	7	39
76	Microdialysis in Parkinsonian patient basal ganglia: acute apomorphine-induced clinical and electrophysiological effects not paralleled by changes in the release of neuroactive amino acids. *Experimental Neurology*, **2001**, 167, 356-65	5.7	37
75	Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up. *Parkinsonism and Related Disorders*, **2017**, 38, 90-92	3.6	35
74	Helicobacter pylori-induced reduction of acute levodopa absorption in Parkinson's disease patients. *Annals of Neurology*, **2001**, 50, 686-7	9.4	35
73	L-dopa modulates motor cortex excitability in Alzheimer's disease patients. *Journal of Neural Transmission*, **2008**, 115, 1313-9	4.3	34
72	123I-FP-CIT in progressive supranuclear palsy and in Parkinson's disease: a SPECT semiquantitative study. *Nuclear Medicine Communications*, **2006**, 27, 381-6	1.6	34
71	Alexithymia is a non-motor symptom of Parkinson disease. *American Journal of Geriatric Psychiatry*, **2012**, 20, 133-41	6.5	32
70	Efficacy and safety profile of prolonged release oxycodone in combination with naloxone (OXN PR) in Parkinson's disease patients with chronic pain. *Journal of Neurology*, **2015**, 262, 2164-70	5.5	31

69	The serendipity case of the pedunculopontine nucleus low-frequency brain stimulation: chasing a gait response, finding sleep, and cognition improvement. *Frontiers in Neurology*, **2013**, 4, 68	4.1	31
68	Physical activity changes and correlate effects in patients with Parkinson's disease during COVID-19 lockdown. *Movement Disorders Clinical Practice*, **2020**, 7, 797	2.2	29
67	Blood dendritic cell frequency declines in idiopathic Parkinson's disease and is associated with motor symptom severity. *PLoS ONE*, **2013**, 8, e65352	3.7	28
66	Involvement of Subcortical Brain Structures During Olfactory Stimulation in Multiple Chemical Sensitivity. *Brain Topography*, **2016**, 29, 243-52	4.3	25
65	Reduced GABA Content in the Motor Thalamus during Effective Deep Brain Stimulation of the Subthalamic Nucleus. *Frontiers in Systems Neuroscience*, **2011**, 5, 17	3.5	25
64	Homovanillic acid in CSF of mild stage Parkinson's disease patients correlates with motor impairment. *Neurochemistry International*, **2017**, 105, 58-63	4.4	24
63	Cardiac sympathetic denervation is not related to nigrostriatal degeneration in Parkinson's disease. *Annals of Nuclear Medicine*, **2013**, 27, 444-51	2.5	24
62	Anosognosia for cognitive and behavioral symptoms in Parkinson's disease with mild dementia and mild cognitive impairment: Frequency and neuropsychological/neuropsychiatric correlates. *Parkinsonism and Related Disorders*, **2018**, 54, 62-67	3.6	23
61	Spontaneous sleep modulates the firing pattern of parkinsonian subthalamic nucleus. *Experimental Brain Research*, **2006**, 168, 277-80	2.3	23
60	An electrophysiological study of D2 dopaminergic actions in normal human retina: a tool in Parkinson's disease. *Neuroscience Letters*, **1992**, 140, 125-8	3.3	22
59	Optic Nerve Dysfunction in Obstructive Sleep Apnea: An Electrophysiological Study. *Sleep*, **2016**, 39, 19-23	1.1	21
58	Quality of life in Parkinson's disease: Italian validation of the Parkinson's Disease Questionnaire (PDQ-39-IT). *Neurological Sciences*, **2018**, 39, 1903-1909	3.5	21
57	Serotonin impairment in CSF of PD patients, without an apparent clinical counterpart. *PLoS ONE*, **2014**, 9, e101763	3.7	20
56	Sad and happy facial emotion recognition impairment in progressive supranuclear palsy in comparison with Parkinson's disease. *Parkinsonism and Related Disorders*, **2012**, 18, 871-5	3.6	20
55	Neuropsychiatric and cognitive profile of early Richardson's syndrome, Progressive Supranuclear Palsy-parkinsonism and Parkinson's disease. *Parkinsonism and Related Disorders*, **2017**, 45, 50-56	3.6	19
54	Autonomic Function Tests and MIBG in Parkinson's Disease: Correlation to Disease Duration and Motor Symptoms. *CNS Neuroscience and Therapeutics*, **2015**, 21, 727-32	6.8	19
53	A non-comparative assessment of tolerability and efficacy of duloxetine in the treatment of depressed patients with Parkinson's disease. *Expert Opinion on Pharmacotherapy*, **2012**, 13, 2269-80	4	19
52	When Cognitive Decline and Depression Coexist in the Elderly: CSF Biomarkers Analysis Can Differentiate Alzheimer's Disease from Late-Life Depression. *Frontiers in Aging Neuroscience*, **2018**, 10, 38	5.3	18

51	Sleep-wake cycle and effects of cabergoline monotherapy in de novo Parkinson's disease patients. An ambulatory polysomnographic study. *Journal of Neurology*, **2008**, 255, 1032-7	5.5	17
50	Daytime sleepiness may be an independent symptom unrelated to sleep quality in Parkinson's disease. *Journal of Neurology*, **2019**, 266, 636-641	5.5	16
49	Young-onset and late-onset Parkinson's disease exhibit a different profile of fluid biomarkers and clinical features. *Neurobiology of Aging*, **2020**, 90, 119-124	5.6	15
48	Catecholamine-Based Treatment in AD Patients: Expectations and Delusions. *Frontiers in Aging Neuroscience*, **2015**, 7, 67	5.3	15
47	Safinamide effect on sleep disturbances and daytime sleepiness in motor fluctuating Parkinson's disease patients: A validated questionnaires-controlled study. *Parkinsonism and Related Disorders*, **2018**, 57, 80-81	3.6	15
46	The early course of affective and cognitive symptoms in de novo patients with Parkinson's disease. *Journal of Neurology*, **2014**, 261, 1126-32	5.5	14
45	Cerebral glucose metabolism in idiopathic REM sleep behavior disorder is different from tau-related and Β-synuclein-related neurodegenerative disorders: A brain [18F]FDG PET study. *Parkinsonism and Related Disorders*, **2019**, 64, 97-105	3.6	13
44	CSF and clinical hallmarks of subcortical dementias: focus on DLB and PDD. *Journal of Neural Transmission*, **2012**, 119, 861-75	4.3	12
43	Effective treatment of restless legs syndrome by safinamide in Parkinson's disease patients. *Sleep Medicine*, **2018**, 41, 113-114	4.6	11
42	Mechanisms of action underlying the efficacy of deep brain stimulation of the subthalamic nucleus in Parkinson's disease: central role of disease severity. *European Journal of Neuroscience*, **2019**, 49, 805-816	3.5	11
41	The impact of rotigotine on cardiovascular autonomic function in early Parkinson's disease. *European Neurology*, **2012**, 68, 187-92	2.1	11
40	Cerebrospinal-fluid Alzheimer's Disease Biomarkers and Blood-Brain Barrier Integrity in a Natural Population of Cognitive Intact Parkinson's Disease Patients. *CNS and Neurological Disorders - Drug Targets*, **2017**, 16, 339-345	2.6	11
39	Hedonic tone and its mood and cognitive correlates in Parkinson's disease. *Depression and Anxiety*, **2013**, 30, 85-91	8.4	10
38	Does 123I-MIBG scintigraphy really assist the diagnosis of Parkinson's disease?. *Parkinsonism and Related Disorders*, **2013**, 19, 772-3	3.6	10
37	Successful subthalamic stimulation, but levodopa-induced dystonia, in a genetic Parkinson's disease. *Neurological Sciences*, **2013**, 34, 383-6	3.5	10
36	Continuous Positive Airway Pressure Treatment May Improve Optic Nerve Function in Obstructive Sleep Apnea: An Electrophysiological Study. *Journal of Clinical Sleep Medicine*, **2018**, 14, 953-958	3.1	8
35	Restless legs syndrome and poliomyelitis: new evidences of an old observation?. *Frontiers in Neurology*, **2015**, 6, 23	4.1	6
34	Depressive symptoms in Parkinson's disease and in non-neurological medical illnesses. *Neuropsychiatric Disease and Treatment*, **2013**, 9, 389-96	3.1	6

33	Alexithymia and anhedonia in early Richardson's syndrome and progressive supranuclear palsy with predominant parkinsonism. *Brain and Behavior*, **2019**, 9, e01448	3.4	6
32	Sleep problems affect quality of life in Parkinson's disease along disease progression. *Sleep Medicine*, **2021**, 81, 307-311	4.6	5
31	Does fatigue in Parkinson's disease correlate with autonomic nervous system dysfunction?. *Neurological Sciences*, **2018**, 39, 2169-2174	3.5	5
30	Increased Noradrenaline as an Additional Cerebrospinal Fluid Biomarker in PSP-Like Parkinsonism. *Frontiers in Aging Neuroscience*, **2020**, 12, 126	5.3	4
29	Transient parkinsonism after unilateral midbrain stroke: a compensatory intervention from the healthy side?. *Neurological Sciences*, **2014**, 35, 2013-5	3.5	4
28	Rotigotine effect on sleep in a de novo Parkinson's Disease patient affected by periodic limb movement disorder. *Parkinsonism and Related Disorders*, **2015**, 21, 1476-8	3.6	4
27	Dyspnea perception and neurological symptoms in non-severe COVID-19 patients. *Neurological Sciences*, **2020**, 41, 2671-2674	3.5	4
26	Frequency of Non-motor Symptoms in Parkinson's Patients With Motor Fluctuations. *Frontiers in Neurology*, **2021**, 12, 678373	4.1	4
25	Depressive and anxiety symptoms in patients with SARS-CoV2 infection. *Journal of Affective Disorders*, **2021**, 278, 339-340	6.6	4
24	Psychiatric profile of motor subtypes of de novo drug-naïve Parkinson's disease patients. *Brain and Behavior*, **2018**, 8, e01094	3.4	4
23	Pitolisant for treating narcolepsy comorbid with Parkinson's disease. *Sleep Medicine*, **2020**, 69, 86-87	4.6	3
22	Epstein-Barr virus neuraxis infection as a trigger for central nervous system demyelinating processes: a case report. *Multiple Sclerosis Journal*, **2013**, 19, 380-1	5	3
21	Cognitive and Neuropsychiatric Profiles in Idiopathic Rapid Eye Movement Sleep Behavior Disorder and Parkinson's Disease. *Journal of Personalized Medicine*, **2021**, 11,	3.6	3
20	Dopaminergic involvement in a drummer with focal dystonia: A case study. *Clinical Neurology and Neurosurgery*, **2018**, 166, 54-55	2	2
19	Commentary: Clinical Correlates of Raphe Serotonergic Dysfunction in Early Parkinson's Disease. *Frontiers in Neurology*, **2015**, 6, 261	4.1	2
18	Clinical course of paroxysmal dyskinesias throughout pregnancy. *Parkinsonism and Related Disorders*, **2020**, 80, 19-20	3.6	2
17	Laterality of Auditory Dysfunction in Parkinson's Disease. *Movement Disorders*, **2020**, 35, 1283-1284	7	2
16	Adult-onset sporadic chorea: real-world data from a single-centre retrospective study. *Neurological Sciences*, **2021**, 1	3.5	2

15	Sudomotor and cardiovascular autonomic function in de novo Parkinson's disease assessed by sudoscan and cardiovascular reflexes. *Journal of the Neurological Sciences*, **2021**, 427, 117502	3.2	2
14	Motor and Non-motor Effects of PPN-DBS in PD Patients: Insights from Intra-operative Electrophysiology. *Advances in Behavioral Biology*, **2009**, 573-587		2
13	Neurotrophins as Therapeutic Agents for Parkinson's Disease; New Chances From Focused Ultrasound?. *Frontiers in Neuroscience*, **2022**, 16, 846681	5.1	2
12	Unraveling predictors affecting compliance to MRI in Parkinson's disease. *Parkinsonism and Related Disorders*, **2015**, 21, 964-7	3.6	1
11	Therapy for dyskinesias in Parkinson's disease patients. *Future Neurology*, **2010**, 5, 277-299	1.5	1
10	Biomarkers of Cerebral Glucose Metabolism and Neurodegeneration in Parkinson's Disease: A Cerebrospinal Fluid-Based Study. *Journal of Parkinson's Disease*, **2021**,	5.3	1
9	Strength and weaknesses of cerebrospinal fluid biomarkers in Alzheimer's disease and possible detection of overlaps with frailty process. *CNS and Neurological Disorders - Drug Targets*, **2013**, 12, 538-46	2.6	1
8	The Retinal Posterior Pole in Early Parkinson's Disease: A Fundus Perimetry and SD-OCT Study. *Clinical Ophthalmology*, **2021**, 15, 4005-4014	2.5	1
7	Lateralization of cochlear dysfunction as a specific biomarker of Parkinson's disease. *Brain Communications*, **2020**, 2, fcaa144	4.5	1
6	Deep brain stimulation in Parkinson's disease patients and routine 6-OHDA rodent models: Synergies and pitfalls. *European Journal of Neuroscience*, **2021**, 53, 2322-2343	3.5	1
5	Effects of melatonin prolonged-release on both sleep and motor symptoms in Parkinson's disease: a preliminary evidence.. *Neurological Sciences*, **2022**, 1	3.5	0
4	Not just a Snapshot: An Italian Longitudinal Evaluation of Stability of Gut Microbiota Findings in Parkinson's Disease. *Brain Sciences*, **2022**, 12, 739	3.4	0
3	Sleep and wake impairment in patients with SARS-CoV2 infection. *Sleep Medicine*, **2020**, 73, 177-178	4.6	
2	Dbs in Parkinsonian Subthalamic Nucleus: Electrophysiological and Biochemical Changes. *Advances in Behavioral Biology*, **2002**, 3-12		
1	Restless legs syndrome is highly prevalent in patients with postpolio syndrome. *Sleep Medicine*, **2018**, 41, 112	4.6	